Mr. Thomas O'Shaughnessy reports

ONCO-INNOVATIONS INITIATES THREE-SPECIES HEPATOCYTE AND MICROSOME METABOLISM STUDIES FOR ONC010

Onco-Innovations Ltd. has initiated hepatocyte and liver microsome metabolism studies for ONC010, the company's lead nanoparticle-formulated PNKP inhibitor. The program is designed to characterize intrinsic clearance, metabolic degradation pathways and species-specific metabolism to support future toxicology studies, pharmacokinetic modelling, dose selection and regulatory submissions.

The studies are being conducted by Nucro-Technics, one of Canada's leading providers of investigational-new-drug-enabling preclinical development services and will evaluate the metabolic stability of ONC010 across human, rat and dog systems. Using both hepatocytes and liver microsomes provides complementary information because each system captures different aspects of liver metabolism. This approach is intended to help the company compare broader cell-based metabolic activity with enzyme-focused metabolism, with the aim of providing a more complete understanding of how ONC010 is processed across relevant test systems. The work forms part of Onco-Innovations' integrated IND-enabling development strategy and complements continuing ADME, bioanalytical, manufacturing, formulation and clinical translation activities.

"Hepatocyte and microsome studies are foundational components of modern oncology drug development. The data generated are intended to help characterize the metabolic profile of ONC010 and to potentially contribute to dose selection, safety assessment and overall development planning," Dr. Islam Mohamed, chief medical officer of Onco-Innovations.

"The initiation of IND-enabling preclinical studies marks an important milestone as the company advances ONC010 toward our first-in-human study. Understanding how the molecule behaves across relevant species is critical for designing future toxicology studies and informing clinical translation strategies," stated Thomas O'Shaughnessy, chief executive officer of Onco-Innovations.

About Onco-Innovations Ltd.

Onco-Innovations is a Canadian-based company dedicated to cancer research and treatment, specializing in oncology. Onco's mission is to pursue the prevention and treatment of cancer through pioneering research and innovative solutions. The company has secured an exclusive worldwide licence to patented technology that targets solid tumours.

We seek Safe Harbor.